Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Localized prostate cancer: Radiotherapy without ADT shows no overall survival benefit

Key clinical point: In patients with intermediate- or high-risk prostate cancer treated with external beam radiotherapy (EBRT), the addition of androgen deprivation therapy (ADT) improves survival compared with the addition of a brachytherapy boost (BT).

Major finding: ADT+EBRT significantly improved overall survival (OS) vs. EBRT alone (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.62-0.81). In a network meta-analysis, EBRT+ADT significantly improved OS vs. EBRT+brachytherapy (HR, 0.68; 95% CI, 0.52-0.89).

Study details: A network meta-analysis of 6 trials comparing EBRT with or without ADT (n = 4,663), and 3 comparing EBRT with or without BT (n = 718).

Disclosures: This study was supported, in part, by the National Institutes of Health Grant, the Prostate Cancer Foundation, and generous philanthropic gifts from patients. The authors reported ties with various pharmaceutical companies.


Jackson WC et al. J Clin Oncol. 2020 May 12. doi: 10.1200/JCO.19.03217.